QQ客服 官方微博 反馈留言

	Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy
	Zhang, Jing; Wang, Tianqi; Mu, Shengjun; Olerile, Livesey D.; Yu, Xiaoyue; Zhang, Na
刊名	NANOMEDICINE
	2017
卷号	12期号:8页码:911-925
关键词	biomacromolecule/lipid hybrid nanoparticles enzyme-responsive HCC hyaluronic acid sorafenib
DOI	10.2217/nnm-2016-0402
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4589473
专题	山东大学
作者单位	Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Peoples R Chin
推荐引用方式 GB/T 7714	Zhang, Jing,Wang, Tianqi,Mu, Shengjun,et al. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy[J]. NANOMEDICINE,2017,12(8):911-925.
APA	Zhang, Jing,Wang, Tianqi,Mu, Shengjun,Olerile, Livesey D.,Yu, Xiaoyue,&Zhang, Na.(2017).Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.NANOMEDICINE,12(8),911-925.
MLA	Zhang, Jing,et al."Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy".NANOMEDICINE 12.8(2017):911-925.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。